Search for: "Rivas v. State" Results 81 - 100 of 113
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Jul 2010, 9:10 am by Stephen Neyman, P.C.
On appeal the defendant argued that the United States Supreme Court's recent decision in Melendez-Diaz v. [read post]
3 Mar 2010, 5:55 am
Rivas, "Rivas II", 2009 Ohio LEXIS 861 (Ohio Mar. 31, 2009). Newman v. [read post]
20 Nov 2009, 4:01 am
" "That part of the breach of contract cause of action alleging a breach of professional standards and seeking damages for the alleged shortfall from the settlement and all of plaintiff's legal fees is dismissed as duplicative of the malpractice claim (see Rivas v Raymond Schwartzberg & Assoc., PLLC, 52 AD3d 401 [2008]). [read post]
15 Jul 2009, 2:24 am
Source: Lexology, July 15, 2009 Ohio - Speculation not enough for court to order production of mirror image of hard driveBricker & Eckler LLP"Though this is a criminal case, the Ohio Supreme Court's ruling in State v. [read post]
6 Apr 2009, 3:39 am
  In State v. [read post]
9 Mar 2009, 11:59 am
"Abortion, death penalty wins slow in coming on state-by-state basis," is Mark Pattison's report via Baltimore's Catholic Review.If Roe v. [read post]
28 Jan 2009, 4:15 am
For a more detailed summary click here.Carlos Rivas v. [read post]
2 Sep 2008, 5:17 pm
State of Tennessee, No. 06-6208 In civil rights suit alleging that city police discriminated against plaintiffs in violation of the Ame [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]